HitGen(SH:688222) Xin Lang Zheng Quan·2025-10-30 11:33Core Viewpoint - Chengdu Xian Dao is a leading enterprise in the global DEL technology drug research and development field, with significant technical advantages in new drug discovery and optimization, making it highly valuable for investment [1] Business Performance - In Q3 2025, Chengdu Xian Dao reported revenue of 370 million yuan, ranking 23rd among 29 companies in the industry, while the industry leader, WuXi AppTec, achieved revenue of 32.857 billion yuan [2] - The company's net profit for the same period was 91.758 million yuan, ranking 13th in the industry, with the top performer, WuXi AppTec, reporting a net profit of 12.206 billion yuan [2] Financial Ratios - As of Q3 2025, Chengdu Xian Dao's debt-to-asset ratio was 22.56%, slightly below the industry average of 22.79% [3] - The company's gross profit margin was 54.85%, higher than the industry average of 37.70% [3] Leadership and Compensation - The chairman and general manager, Jin Li, received a salary of 3.3408 million yuan in 2024, unchanged from 2023 [4] Shareholder Information - As of September 30, 2025, the number of A-share shareholders increased by 13.63% to 20,700, while the average number of circulating A-shares held per shareholder decreased by 11.99% [5] - Chengdu Xian Dao focuses on small molecule and nucleic acid new drug discovery and optimization, supported by four core technology platforms [5] Revenue Projections - Revenue projections for Chengdu Xian Dao from 2025 to 2027 are 504 million yuan, 608 million yuan, and 739 million yuan, representing year-on-year growth rates of 17.95%, 20.70%, and 21.57% respectively [5]